An interventional study of KardiaRx ECG Screening and AI interpretation of ECG in Cardiomyopathy, sponsored by Mayo Clinic. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Mayo Clinic · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Cardiomyopathies by Mayo Clinic — 4 open to participants now, 4 under way, none of them phase 3. Cardiomyopathies · Mayo Clinic.
Among the 11 studies in Cardiomyopathies by Mayo Clinic, this one is the only one that started in 2024, is one of 2 with no phase, and was the 10th registered.
556 studies on the registry are indexed under Cardiomyopathies; 153 are open to participants now.
Browse Cardiomyopathies studies →4 of the 11 studies in Cardiomyopathies by Mayo Clinic are open now, in 2 countries. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States, United Kingdom
Healthy volunteers
Mayo Clinic · Sites in United States
Ages 18–50
By country, each count listing its studies:
Of the 116 Cardiomyopathies studies recruiting now, 70 (60%) set no upper age limit and 18 (16%) stop at 75 or younger; 35 take children under 18; 22 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 119 is above the median of 51 across 268 interventional studies indexed under Cardiomyopathies.
Median enrollment 93 across the 6 interventional studies, 600 across the 5 observational. Of the 7 that completed or were terminated, 4 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
Mayo Clinic is the lead sponsor of 3,272 studies on the registry; 672 are open to participants now.
Of its 452 completed or terminated interventional studies of FDA-regulated products, 322 (71%) have results posted.
1 of the studies in Cardiomyopathies by Mayo Clinic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03049254Mayo ClinicMayo AVC Registry and Biobank | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Cardiomyopathies by Mayo Clinic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the feasibility and impact of screening FDR of DCM probands using a mobile ECG with the ability to transmit the ECG for cloud-based AI analysis to detect reduced left ventricular ejection fraction (LVEF). This protocol will examine the impact of incorporating the screening AI enhanced ECG into standard of care recommendations.
The criteria were revised on the registry on Oct 13, 2026. See what changed
Inclusion Criteria (Proband)
Inclusion Criteria (FDR)
Exclusion Criteria (Proband)
Ischemic cause of reduced LVEF
Exclusion Criteria (FDR)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects who are first-degree relatives of patients with DCM
Diagnostic Test: KardiaRx ECG Screening and AI interpretation of ECG
Subjects who are diagnosed with DCM (dilated cardiomyopathy).
Diagnostic Test: KardiaRx ECG Screening and AI interpretation of ECG
The Kardia 6-lead device is an ambulatory, wireless device that connects to a smartphone. The KardiaRx App processes the signal acquired from the Kardia device into a real-time ECG. ECG will be interpreted by an AI algorithm
Number of First-Degree Relatives to Complete the AI-ECG
Measured by the number of subjects who had a complete transmission from the Kardia 6-lead device to the AI-ECG algorithm.
Time frame: Baseline
Number of First-Degree Relatives to Complete Cardiac Screening
The number of subjects who completed cardiac screening (i.e. had a scheduled or Completed TTE or had a scheduled or completed clinician visit for the purposes of generating a cardiac evaluation).
Time frame: Baseline
Number of Subjects With an AI ECG-Predicted Left Ventricular Ejection Fraction ≤45%
Number of participants with a positive AI-ECG result, defined as an AI-predicted left ventricular ejection fraction (LVEF) of 45% or less. ECGs were obtained using the AliveCor Kardia 6L device and analyzed using FDA-cleared AI software designed to detect reduced LVEF (≤45%).
Time frame: Baseline
| Milestone | First Degree Relatives | DCM (Dilated Cardiomyopathy) Patients |
|---|---|---|
| Started | 66 | 47 |
| Completed | 58 | 47 |
| Not completed | 8 | 0 |
| Withdrew: Did not complete ecg recording | 8 | 0 |
Measured by the number of subjects who had a complete transmission from the Kardia 6-lead device to the AI-ECG algorithm.
| Participants | First Degree Relatives | DCM (Dilated Cardiomyopathy) Patients |
|---|---|---|
| Number of First-Degree Relatives to Complete the AI-ECG | 58 | — |
The number of subjects who completed cardiac screening (i.e. had a scheduled or Completed TTE or had a scheduled or completed clinician visit for the purposes of generating a cardiac evaluation).
| Participants | First Degree Relatives | DCM (Dilated Cardiomyopathy) Patients |
|---|---|---|
| Number of First-Degree Relatives to Complete Cardiac Screening | 14 | — |
Number of participants with a positive AI-ECG result, defined as an AI-predicted left ventricular ejection fraction (LVEF) of 45% or less. ECGs were obtained using the AliveCor Kardia 6L device and analyzed using FDA-cleared AI software designed to detect reduced LVEF (≤45%).
| Participants | First Degree Relatives | DCM (Dilated Cardiomyopathy) Patients |
|---|---|---|
| Number of Subjects With an AI ECG-Predicted Left Ventricular Ejection Fraction ≤45% | 15 | — |
Collected over Adverse events were collected from the time of informed consent through study completion, approximately 2 months.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| First Degree Relatives | 0/66 (0%) | 0/66 (0%) | 0/66 (0%) |
| DCM (Dilated Cardiomyopathy) Patients | 0/47 (0%) | 0/47 (0%) | 0/47 (0%) |
| Age, Continuous(years) | First Degree Relatives | DCM (Dilated Cardiomyopathy) Patients | Total |
|---|---|---|---|
| Median | 45 (36 to 61) | 65 (57 to 71) | 56 (40 to 68) |
| Sex: Female, Male(Participants) | First Degree Relatives | DCM (Dilated Cardiomyopathy) Patients | Total |
|---|---|---|---|
| Female | 33 | 21 | 54 |
| Male | 33 | 26 | 59 |
| Ethnicity (NIH/OMB)(Participants) | First Degree Relatives | DCM (Dilated Cardiomyopathy) Patients | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 1 | 4 |
| Not Hispanic or Latino | 62 | 44 | 106 |
| Unknown or Not Reported | 1 | 2 | 3 |
| Race (NIH/OMB)(Participants) | First Degree Relatives | DCM (Dilated Cardiomyopathy) Patients | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 2 |
| Asian | 2 | 2 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 1 | 3 |
| White | 60 | 42 | 102 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Region of Enrollment(participants) | First Degree Relatives | DCM (Dilated Cardiomyopathy) Patients | Total |
|---|---|---|---|
| United States | 66 | 47 | 113 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2024 to primary completion in Sep 2025, 11 months.
Results were first posted in Oct 2026, 1 year after primary completion.
Of 41 non-industry interventional studies with no phase under Cardiomyopathies, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 53. This study's 11 months is below that.
Counting every sponsor, half of 52 studies reached it within 39 months; a quarter within 23 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.